BMX negatively regulates BAK function, thereby increasing apoptotic resistance to chemotherapeutic drugs

Cancer Research

Volumn 75, Issue 7, 2015, Pages 1345-1355

  Fox, Joanna L ^a,b   Storey, Alan ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MRC TOXICOLOGY UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BMX PROTEIN; CAMPTOTHECIN; DOCETAXEL; ETOPOSIDE; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 21; PROTEIN BAK; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; BAK1 PROTEIN, HUMAN; BMX PROTEIN, HUMAN; PTPN21 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CANCER RESISTANCE; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; TRIPLE NEGATIVE BREAST CANCER; BREAST TUMOR; COLORECTAL TUMOR; DRUG RESISTANCE; FEMALE; MALE; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; PROSTATE TUMOR; PROTEIN PROCESSING; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BREAST NEOPLASMS; CAMPTOTHECIN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; HUMANS; MALE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TYROSINE PHOSPHATASES, NON-RECEPTOR; PROTEIN-TYROSINE KINASES;

EID: 84941686309     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-1340     Document Type: Article

References (48)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
3. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006;25:4798-811.
4. Makin G, Dive C. Apoptosis and cancer chemotherapy. Trends Cell Biol 2001;11:S22-6.
5. Makin G, Hickman JA. Apoptosis and cancer chemotherapy. Cell Tissue Res 2000;301:143-52.
6. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003;22:8590-607.
7. Galluzzi L, Morselli E, Kepp O, Vitale I, Rigoni A, Vacchelli E, et al. Mitochondrial gateways to cancer. Mol Aspects Med 2010;31:1-20.
8. Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 2010;11:621-32.
9. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008;9:47-59.
10. Chipuk JE, Green DR. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol 2008;18:157-64.
11. Llambi F, Green DR. Apoptosis and oncogenesis: give and take in the BCL-2 family. Curr Opin Genet Dev 2011;21:12-20.
12. Llambi F, Moldoveanu T, Tait SW, Bouchier-Hayes L, Temirov J, McCormick LL, et al. A unified model of mammalian BCL-2 protein family interactions at the mitochondria. Mol Cell 2011;44:517-31.
13. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001;292:727-30.
14. Azad A, Fox J, Leverrier S, Storey A. Blockade of the BAK hydrophobic groove by inhibitory phosphorylation regulates commitment to apoptosis. PLoS ONE 2012;7:e49601.
15. Fox J, Azad A, Ismail F, Storey A. "Licensed to kill": tyrosine dephosphorylation and Bak activation. Cell Cycle 2011;10:598-603.
16. Fox JL, Ismail F, Azad A, Ternette N, Leverrier S, Edelmann MJ, et al. Tyrosine dephosphorylation is required for Bak activation in apoptosis. EMBO J 2010;29:3853-68.
17. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006;24:5652-7.
18. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-34.
19. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011;121:2750-67.
20. Griffiths GJ, Dubrez L, Morgan CP, Jones NA, Whitehouse J, Corfe BM, et al. Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis. J Cell Biol 1999;144:903-14.
21. Waterhouse NJ, Trapani JA. A new quantitative assay for cytochrome c release in apoptotic cells. Cell Death Differ 2003;10:853-5.
22. Dai B, Kim O, Xie Y, Guo Z, Xu K, Wang B, et al. Tyrosine kinase Etk/BMX is up-regulated in human prostate cancer and its overexpression induces prostate intraepithelial neoplasia in mouse. Cancer Res 2006;66:8058-64.
23. Jarvius M, Paulsson J, Weibrecht I, Leuchowius KJ, ersson AC, Wahlby C, et al. In situ detection of phosphorylated platelet-derived growth factor receptor beta using a generalized proximity ligation method. Mol Cell Proteomics 2007;6:1500-9.
24. Guo S, Sun F, Guo Z, Li W, Alfano A, Chen H, et al. Tyrosine kinase ETK/BMX is up-regulated in bladder cancer and predicts poor prognosis in patients with cystectomy. PLoS One 2011;6:e17778.
25. Bagheri-Yarmand R, Mandal M, Taludker AH, Wang RA, Vadlamudi RK, Kung HJ, et al. Etk/Bmx tyrosine kinase activates Pak1 and regulates tumorigenicity of breast cancer cells. J Biol Chem 2001;276:29403-9.
26. Paavonen K, Ekman N, Wirzenius M, Rajantie I, Poutanen M, Alitalo K. Bmx tyrosine kinase transgene induces skin hyperplasia, inflammatory angiogenesis, and accelerated wound healing. Mol Biol Cell 2004;15:4226-33.
27. Zhuang J, Tu X, Cao K, Guo S, Mao X, Pan J, et al. The expression and role of tyrosine kinase ETK/BMX in renal cell carcinoma. J Exp Clin Cancer Res 2014;33:25.
28. Dai B, Chen H, Guo S, Yang X, Linn DE, Sun F, et al. Compensatory upregulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells. Cancer Res 2010;70:5587-96.
29. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
30. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012;486:405-9.
31. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012;486:400-4.
32. Kyriaki Michailidou, Per Hall, Anna Gonzalez-Neira, Maya Ghoussaini, Joe Dennis, Roger l Milne, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 2013;45:353-61.
33. De Laurentiis M, Cianniello D, Caputo R, Stanzione B, Arpino G, Cinieri S, et al. Treatment of triple negative breast cancer (TNBC): current options and future perspectives. Cancer Treat Rev 2010;36 (Suppl 3):S80-6.
34. Tsai YT, Su YH, Fang SS, Huang TN, Qiu Y, Jou YS, et al. Etk, a Btk family tyrosine kinase, mediates cellular transformation by linking Src to STAT3 activation. Mol Cell Biol 2000;20:2043-54.
35. Jui HY, Tseng RJ, Wen X, Fang HI, Huang LM, Chen KY, et al. Protein-tyrosine phosphatase D1, a potential regulator and effector for Tec family kinases. J Biol Chem 2000;275:41124-32.
36. Barr AJ, Ugochukwu E, Lee WH, King ON, Filippakopoulos P, Alfano I, et al. Large-scale structural analysis of the classical human protein tyrosine phosphatome. Cell 2009;136:352-63.
37. Cardone L, Carlucci A, Affaitati A, Livigni A, DeCristofaro T, Garbi C, et al. Mitochondrial AKAP121 binds and targets protein tyrosine phosphatase D1, a novel positive regulator of src signaling. Mol Cell Biol 2004;24:4613-26.
38. Hobbs S, Jitrapakdee S, Wallace JC. Development of a bicistronic vector driven by the human polypeptide chain elongation factor 1alpha promoter for creation of stable mammalian cell lines that express very high levels of recombinant proteins. Biochem Biophys Res Commun 1998;252:368-72.
39. Jarboe JS, Dutta S, Velu SE, Willey CD. Mini-review: bmx kinase inhibitors for cancer therapy. Recent Pat Anticancer Drug Discov 2013;8:228-38.
40. Xue LY, Qiu Y, He J, Kung HJ, Oleinick NL. Etk/Bmx, a PH-domain containing tyrosine kinase, protects prostate cancer cells from apoptosis induced by photodynamic therapy or thapsigargin. Oncogene 1999;18:3391-8.
41. Kim O, Jiang T, Xie Y, Guo Z, Chen H, Qiu Y. Synergism of cytoplasmic kinases in IL6-induced ligand-independent activation of androgen receptor in prostate cancer cells. Oncogene 2004;23:1838-44.
42. Guryanova OA, Wu Q, Cheng L, Lathia JD, Huang Z, Yang J, et al. Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell 2011;19:498-511.
43. Jiang X, Borgesi RA, McKnight NC, Kaur R, Carpenter CL, Balk SP. Activation of nonreceptor tyrosine kinase Bmx/Etk mediated by phosphoinositide 3-kinase, epidermal growth factor receptor, and ErbB3 in prostate cancer cells. J Biol Chemi 2007;282:32689-98.
44. Vogt PK, Hart JR. PI3K and STAT3: a new alliance. Cancer Discov 2011;1:481-86.
45. Guo L, Zhou Y, Sun Y, Zhang F. Non-receptor tyrosine kinase Etk regulation of drug resistance in small-cell lung cancer. Eur J Cancer 2010;46:636-41.
46. Zhang Z, Zhu W, Zhang J, Guo L. Tyrosine kinase Etk/BMX protects nasopharyngeal carcinoma cells from apoptosis induced by radiation. Cancer Biol Ther 2011;11:690-8.
47. Chau CH, Chen KY, Deng HT, Kim KJ, Hosoya K, Terasaki T, et al. Coordinating Etk/Bmx activation and VEGF upregulation to promote cell survival and proliferation. Oncogene 2002;21:8817-29.
48. Hur W, Velentza A, Kim S, Flatauer L, Jiang X, Valente D, et al. Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase. Bioorg Med Chem Lett 2008;18:5916-9.